BioServe introduced ControlMATCH, a new line of fully annotated control DNA and serum samples designed to help biomedical researchers efficiently validate new biomarkers and early-stage clinical trial drug candidates. Leveraging BioServe’s Global Repository of 600,000 human biological samples, ControlMATCH allows researchers to select and match control samples to the specific needs of their own DNA and/or serum-based studies.
ControlMATCH DNA and serum controls will initially cover type 2 diabetes, hypertension and hyperlipidemia, and extend to other disease states in early 2008.
www.genomicsinc.com
This article was published in Drug Discovery & Development magazine: Vol. 11, No. 1, January, 2008, pp. 54.
Filed Under: Genomics/Proteomics
![A display of DNA sequencing output from an automated ABI 373 sequencer. [National Human Genome Research Institute (NHGRI)]](https://www.drugdiscoverytrends.com/wp-content/uploads/2024/06/51187236177_b7b566a401_k-268x170.jpg)